Literature DB >> 1645794

The functionally active IE2 immediate-early regulatory protein of human cytomegalovirus is an 80-kilodalton polypeptide that contains two distinct activator domains and a duplicated nuclear localization signal.

M C Pizzorno1, M A Mullen, Y N Chang, G S Hayward.   

Abstract

The IE2 region of the human cytomegalovirus (CMV) strain Towne major immediate-early (MIE) gene encodes a transcriptional transactivator that stimulates expression from a variety of heterologous target promoters but specifically down-regulates its own promoter. By immunofluorescence and Western immunoblot analysis with monospecific peptide antisera, we found that human CMV MIE exon 5 encodes four overlapping polypeptides, two present at immediate-early times (80 and 55 kDa) and two others detected only at late times after infection (55 and 40 kDa). However, only the 80-kDa version (579 amino acids), which is derived from the small upstream exons 2 and 3 fused to the intact exon 5 region, was functionally active in both transactivation and autoregulation as assessed by cotransfection experiments. These results confirm the corrected assignment of the coding capacity of the exon 5 region based on amino acid homology with the equivalent IE2 protein from simian CMV (Colburn). In transient DNA transfection assays, IE2 expression plasmids also produced a predominant full-length 80-kDa protein, which was localized in a distinctive reticular pattern in the nucleus. Two short basic nuclear localization signals in IE2 were identified by deletion analysis and by conversion of a test cytoplasmic herpes simplex virus protein into a form that localized in the nucleus after insertion of either of these two human CMV motifs. Functional assays with MIE region plasmids containing deletions or truncations in exon 5 revealed that both transactivation and autoregulation required several distinct domains within the COOH half of the IE2 protein, whereas a region between codons 99 and 194 could be discarded. Three segments at the NH2 end of the protein between codons 1 to 85, 86 to 98, and 195 to 290 were also essential for transactivation but played no role in autoregulation. Finally, in domain swap experiments, GAL4-fusion proteins containing either an NH2-terminal 51-amino-acid domain from exon 3 (codons 25 to 85) or the COOH-terminal 33-amino-acid domain from exon 5 (codons 544 to 579) identified two distinct activator domains from IE2, both of which have acidic characteristics.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645794      PMCID: PMC241415     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Transcription activation by the adenovirus E1a protein.

Authors:  J W Lillie; M R Green
Journal:  Nature       Date:  1989-03-02       Impact factor: 49.962

2.  Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1.

Authors:  J D Mosca; D P Bednarik; N B Raj; C A Rosen; J G Sodroski; W A Haseltine; G S Hayward; P M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  Participation of two human cytomegalovirus immediate early gene regions in transcriptional activation of adenovirus promoters.

Authors:  M J Tevethia; D J Spector; K M Leisure; M F Stinski
Journal:  Virology       Date:  1987-12       Impact factor: 3.616

4.  Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus.

Authors:  M G Davis; S C Kenney; J Kamine; J S Pagano; E S Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

5.  Functional dissection of VP16, the trans-activator of herpes simplex virus immediate early gene expression.

Authors:  S J Triezenberg; R C Kingsbury; S L McKnight
Journal:  Genes Dev       Date:  1988-06       Impact factor: 11.361

6.  The IE2 gene products of human cytomegalovirus specifically down-regulate expression from the major immediate-early promoter through a target sequence located near the cap site.

Authors:  M C Pizzorno; G S Hayward
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

7.  Identification of a human cytomegalovirus virus DNA segment that complements an adenovirus 5 immediate early mutant.

Authors:  D J Spector; M J Tevethia
Journal:  Virology       Date:  1986-06       Impact factor: 3.616

8.  Identification of sequence requirements and trans-acting functions necessary for regulated expression of a human cytomegalovirus early gene.

Authors:  S I Staprans; D K Rabert; D H Spector
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

9.  trans-activation and autoregulation of gene expression by the immediate-early region 2 gene products of human cytomegalovirus.

Authors:  M C Pizzorno; P O'Hare; L Sha; R L LaFemina; G S Hayward
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

10.  The carboxy-terminal domain shared by the bovine papillomavirus E2 transactivator and repressor proteins contains a specific DNA binding activity.

Authors:  A A McBride; R Schlegel; P M Howley
Journal:  EMBO J       Date:  1988-02       Impact factor: 11.598

View more
  95 in total

1.  A strong negative transcriptional regulatory region between the human cytomegalovirus UL127 gene and the major immediate-early enhancer.

Authors:  C A Lundquist; J L Meier; M F Stinski
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Viable human cytomegalovirus recombinant virus with an internal deletion of the IE2 86 gene affects late stages of viral replication.

Authors:  Veronica Sanchez; Charles L Clark; Judy Y Yen; Roopashree Dwarakanath; Deborah H Spector
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Conserved regions in the Epstein-Barr virus leader protein define distinct domains required for nuclear localization and transcriptional cooperation with EBNA2.

Authors:  R Peng; J Tan; P D Ling
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  The human cytomegalovirus 80-kilodalton but not the 72-kilodalton immediate-early protein transactivates heterologous promoters in a TATA box-dependent mechanism and interacts directly with TFIID.

Authors:  C Hagemeier; S Walker; R Caswell; T Kouzarides; J Sinclair
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

5.  Human cytomegalovirus pUL83 stimulates activity of the viral immediate-early promoter through its interaction with the cellular IFI16 protein.

Authors:  Ileana M Cristea; Nathaniel J Moorman; Scott S Terhune; Christian D Cuevas; Erin S O'Keefe; Michael P Rout; Brian T Chait; Thomas Shenk
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

6.  Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Authors:  Thomas J Gardner; Cynthia Bolovan-Fritts; Melissa W Teng; Veronika Redmann; Thomas A Kraus; Rhoda Sperling; Thomas Moran; William Britt; Leor S Weinberger; Domenico Tortorella
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

7.  Human cytomegalovirus UL84 localizes to the cell nucleus via a nuclear localization signal and is a component of viral replication compartments.

Authors:  Yiyang Xu; Kelly S Colletti; Gregory S Pari
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Spliced transcripts of human cytomegalovirus.

Authors:  W D Rawlinson; B G Barrell
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

9.  Transcriptional activation by the human cytomegalovirus immediate-early proteins: requirements for simple promoter structures and interactions with multiple components of the transcription complex.

Authors:  D M Lukac; J R Manuppello; J C Alwine
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  UL69 of human cytomegalovirus, an open reading frame with homology to ICP27 of herpes simplex virus, encodes a transactivator of gene expression.

Authors:  M Winkler; S A Rice; T Stamminger
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.